Cortexyme, Inc. (CRTX): Price and Financial Metrics


Cortexyme, Inc. (CRTX): $1.95

0.05 (+2.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CRTX Stock Price Chart Interactive Chart >

Price chart for CRTX

CRTX Price/Volume Stats

Current price $1.95 52-week high $40.66
Prev. close $1.90 52-week low $1.78
Day low $1.86 Volume 272,200
Day high $1.97 Avg. volume 620,672
50-day MA $2.52 Dividend yield N/A
200-day MA $7.57 Market Cap 58.79M

Cortexyme, Inc. (CRTX) Company Bio


Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases.


CRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CRTX Latest Social Stream


Loading social stream, please wait...

View Full CRTX Social Stream

Latest CRTX News From Around the Web

Below are the latest news stories about CORTEXYME INC that investors may wish to consider to help them evaluate CRTX as an investment opportunity.

Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name

SOUTH SAN FRANCISCO, Calif., August 01, 2022--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, provided an overview of its strategic growth plan in conjunction with its corporate name change today. The launch of Quince Therapeutics marks a strategic shift in focus as the company prioritizes the clinical development of its highly differentiated bone-targeting drug platform and lead precision

Yahoo | August 1, 2022

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

SOUTH SAN FRANCISCO, Calif., July 27, 2022--Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics’ go-forward growth strategy and development pipeline plans.

Yahoo | July 27, 2022

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

SOUTH SAN FRANCISCO, Calif., July 27, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company’s lysine gingipain inhibitor in development for the treatment of Alzheimer’s disease and indications with disease pathology associated with the keystone path

Yahoo | July 27, 2022

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

SOUTH SAN FRANCISCO, Calif., June 21, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after ora

Yahoo | June 21, 2022

Cortexyme Appoints June Bray to its Board of Directors

SOUTH SAN FRANCISCO, Calif., June 13, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors.

Yahoo | June 13, 2022

Read More 'CRTX' Stories Here

CRTX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -66.09%
3-year -88.78%
5-year N/A
YTD N/A
2022 0.00%
2021 36.29%
2020 -50.52%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.723 seconds.